Nordic Nanovector's plan to emerge from its current troubles by merging with APIM Therapeutics has hit an insurmountable hurdle – in the shape of its own shareholders.
Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics.<
Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started a restructuring process and called in investment bank Carnegie to help explore
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho